AstraZeneca unit rolls out preemie newspaper ads to fight Synagis limits

Tracy Staton Drugmakers cheer when doctors' groups revise treatment guidelines to include new drugs. What happens when these powerful professional associations change those recommendations ...

AstraZeneca reaches out to Roche with a would-be cancer blockbuster

Damian Garde AstraZeneca has high hopes for the in-development AZD9291, a treatment for lung cancer expected to bring in $ 3 billion a year at its peak, and the drugmaker is working ...

Big Pharma to share abandoned drugs, Actelion M&A rumors resume, Gaza war threatens IPOs

Nick Paul Taylor In this week's EuroBiotech Report, events in Gaza and Ukraine have cast a shadow over Europe, with sections of the Israeli biotech industry among the many groups ...

Can Gilead break into cancer? With Zydelig approval, it gets its chance

Tracy Staton Armed with a brand-new FDA approval for its blood cancer drug Zydelig (idelalisib), Gilead will take on the oncology market. FiercePharma News

BMJ targets Pradaxa safety, scolding Boehringer, FDA and EMA alike

Tracy Staton The BMJ has set off a kerfuffle–and a Twitter campaign–over the safety of Boehringer Ingelheim's blockbuster anticoagulant Pradaxa. FiercePharma News

Novo’s blockbuster diabetes combo nears EU approval

Damian Garde A committee of European Medicines Agency advisers is recommending approval for Novo Nordisk's combination of a long-acting insulin and its blockbuster GLP-1 drug Victoza, ...

Still reeling from China bribery probe, GSK faces corruption scandal in Syria

Arlene Weintraub The British company said Thursday that it had received an email containing allegations from a whistleblower pertaining to bribes paid by GSK's consumer healthcare ...

Gilead’s Zydelig, J&J’s Imbruvica will go toe-to-toe in EU with nod for CLL

Eric Palmer Gilead Sciences, which this week got FDA approval for its new blood cancer drug Zydelig (idelalisib), has now gotten a recommendation for its use in Europe. But competitor ...

Keryx touts its kidney drug with an FDA decision around the corner

Damian Garde Keryx Biopharmaceuticals' in-development Zerenex helped reduce dangerous buildups of phosphorus in patients on kidney dialysis, meeting its goals in a Phase III study ...

Sarepta science officer Krieg ‘terminated’ quietly

Alok Saboo FierceBiotech News

J&J builds 9-month supply of Doxil with creative problem solving

Eric Palmer A Johnson & Johnson exercise in creative problem solving has paid off for doctors and patients who rely on its ovarian cancer drug Doxil, availability of which has been ...

Sarepta’s flash firing tightens the focus on a heavily scrutinized company

Damian Garde Sarepta Therapeutics' terse dismissal of its top scientist on Thursday has led to a swirl of rumors and anonymous-sourced reports of boardroom clashes, incompatible ...
Page 2 of 1212345...10...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS